- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/71 - Receptors; Cell surface antigens; Cell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 1984
10-year publication summary
|
96
|
122
|
145
|
164
|
177
|
158
|
226
|
247
|
177
|
42
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 365 |
139 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
130 |
| Amgen Inc. | 3779 |
33 |
| Immatics Biotechnologies GmbH | 1144 |
31 |
| The Regents of the University of California | 18943 |
26 |
| Board of Regents, The University of Texas System | 5370 |
24 |
| Genentech, Inc. | 3742 |
22 |
| Merck Patent GmbH | 5909 |
20 |
| The Trustees of the University of Pennsylvania | 4122 |
18 |
| City of Hope | 943 |
18 |
| Genzyme Corporation | 1205 |
18 |
| Keros Therapeutics, Inc. | 53 |
17 |
| Novartis AG | 11238 |
16 |
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
16 |
| The Johns Hopkins University | 5377 |
15 |
| Biocon Limited | 228 |
15 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
15 |
| Janssen Biotech, Inc. | 1347 |
14 |
| National Research Council of Canada | 1545 |
14 |
| Precigen Inc | 90 |
13 |
| Other owners | 1370 |